Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31750486 | 0.87 | MAPK1 (0.54) | MAPK1ALDH1A1CYP1A2TSHRPOLB | |
| SCHEMBL16707017 | 0.86 | TSHR (0.60) | MAPK1ALDH1A1CYP1A2TSHRNPC1 | |
| SCHEMBL31138631 | 0.86 | NPSR1 (0.44) | MAPK1ALDH1A1NPC1POLBHPGD | |
| SCHEMBL1968562 | 0.85 | MAPK1 (0.52) | MAPK1ALDH1A1CYP1A2TSHRNPC1 | |
| SCHEMBL24554041 | 0.84 | TSHR (0.47) | MAPK1ALDH1A1CYP1A2TSHRNPC1 | |
| SCHEMBL1971989 | 0.83 | MAPK1 (0.50) | MAPK1ALDH1A1CYP1A2TSHRPOLB | |
| SCHEMBL13263371 | 0.83 | ALDH1A1 (0.47) | ALDH1A1CYP1A2TSHRNPC1POLB | |
| SCHEMBL29517486 | 0.81 | ALDH1A1 (0.46) | MAPK1ALDH1A1CYP1A2TSHRNPC1 | |
| SCHEMBL2826113 | 0.80 | TSHR (0.41) | MAPK1ALDH1A1CYP1A2TSHRNPC1 | |
| SCHEMBL5550880 | 0.79 | NTRK1 (0.41) | MAPK1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168633-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2158207-B1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HOFFMANN LA ROCHE (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | HANCOX TIMOTHY COLIN | 2011-04-28 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-7893060-B2 | Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase | F. HOFFMANN-LA ROCHE AG (GB) | 2011-02-22 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2158207-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F. Hoffmann-Roche AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152390-A1 | THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190769-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PDPK1, PIK3CA, PI4KA | MAPK1 83/4885ALDH1A1 1436/4885CYP1A2 822/4885 |
| US-20110098270-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE | PIK3CA, PIK3CD, PI4KA | MAPK1 253/4885ALDH1A1 2612/4885CYP1A2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.